Conference Materials

First-in-human trial of LB2501, an in vivo CD19/CD20 dual-target CAR-T therapy, in relapsed/refractory B-cell NHL

Xiaoyan Qu, Yajing Zhang, Haisheng Liu, Heng Mei, Kaiyang Ding, Jujuan Wang, Sanmei Wang, Haorui Shen, Zhengxu Sun, Shuangshuang Xing, Guoai Su, Zheng Li, Lin Liu, Ran Li, Hailing Liu, Ling Zhou, Yinrui Jiang, Yongxin Luo, Baoming Nie, Dong Geng, Guowei Fang, Yanjie Xu, Cong Feng, Wenjie Wang, Da Xu, Zhongyuan Tu, Hongchen Zheng, Bing […]

Results from the Phase 1 study of LB2102, a dnTGFBR2-armored, DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC

Zhonglin Hao, Alberto Chiappori, Ben C. Creelan, Reinhold Munker, Paul O. Schwarzenberger, Nitin Patel, Sahista Vahora, Christian Davis, Chuan Wang, Jinghui Zhang, Lijun Xin, Adam J. Schoenfeld, Jacob Sands

Phase 1 study of LB1908, an autologous claudin 18.2-targeted chimeric antigen receptor T-cell product, in subjects with advanced gastroesophageal adenocarcinoma

David B Zhen, Richard T Maziarz, Emerson Y Chen, Christos Fountzilas, Dae Won Kim, Martin Gutierrez, Michael K Gibson, Nicholas DeVito, Alexandria Phan, Benjamin Oshrine, Mythili Koneru, Sahista Vahora, Chuan Wang, Lijun Xin, Christian Davis, Jinghui Zhang, Anthony F Shields

A Phase 1 study of LUCAR-G39D: a novel anti-CD20/CD19 dual-CAR allogeneic γδ T cells in adults with relapsed/refractory B-cell non-Hodgkin lymphoma

Jingwei Yu, Linlin Cao, Lanfang Li, Jing Ming, Zhengzi Qian, Dandan Fan, Lihua Qiu, Xianming Liu, Jiayi Han, Jian Li, Pu Wang, Qing Dai, Yafeng Zhang, Wenjie Wang, Da Xu, Yue Zhu, Cong Feng, Xiaoyu Feng, Jin Liu, Lemei Jia, Ning Chen, Yinrui Jiang, Liping Sun, Qi Zhou, Nan Wang, Yongxin Luo, Kaiyang Ding, Huilai […]

Phase 1 Study of DLL3-targeted CAR-T Cells Armored With dnTGFBR2 in Small-Cell Lung and Large-Cell Neuroendocrine Cancers

Adam J. Schoenfeld, Chiappori A., Creelan B., Munker R., Koneru M., Schwarzenberger P., Vahora S., Davis C., Zhang J., Geng D., Xu D., Wang C., Xin L., Sands J., Hao Z.

Dominant-negative TGFBR2-armored DLL3-targeted CAR-T Cells Maintain TGF-β Resistance, With Early Signals of T-cell Exhaustion Modulation After Expansion in Patients With Small-cell Lung Carcinoma

Chuan Wang, Shuai Yang, Tao Zhao, Wang Zhang, Liping Sun, Zhong Yun, Mythili Koneru, Paul Schwarzenberger, Sahista Vahora, Christian Davis, Anqi Li, Jihong Dai, Luqing Ren, Wen Xie, Kevin Jhun, Zoe Zheng, and Dong Geng

Preliminary results of a phase 1 study of LB1908, an autologous Claudin 18.2-targeted chimeric antigen receptor T-cell product, in patients with advanced gastroesophageal adenocarcinoma

David Zhen, Christos Fountzilas, Richard T. Maziarz, Emerson Y. Chen, Michael K. Gibson, Benjamin Oshrine, Mythili Koneru, Sahista Vahora, Christian Davis, Da Xu, and Anthony F. Shields

Safety, tolerability, and preliminary efficacy results from an ongoing Phase 1 study of LB2102, a dnTGFBR2-armored DLL3-targeted autologous CAR-T cell therapy, in patients with relapsed or refractory SCLC or LCNEC

Jacob Sands, Alberto Chiappori, Ben Creelan, Paul Schwarzenberger, Mythili Koneru, Sahista Vahora, Christian Davis, Da Xu, Chuan Wang, Reinhold Munker, Zhonglin Hao, Adam J. Schoenfeld

Access Legend-sponsored posters and presentations from recent scientific conferences.